Studi clinici aperti all’arruolamento

 

Titolo: CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen

Principal Investigator: Prof. Pierosandro Tagliaferri

Per informazioni sull’arruolamento contattare: Dott.ssa Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com


Titolo: DS8201-A-U306 – “A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects With HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)”

Principal Investigator: Prof. Pierfrancesco Tassone

Per informazioni sull’arruolamento contattare: Dott.ssa Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com


Titolo: MK7902-015 – “Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)”

Principal Investigator: Prof. Pierfrancesco Tassone

Per informazioni sull’arruolamento contattare: Dott.ssa Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com


Titolo: ROME – “The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy”

Principal Investigator: Prof. Pierosandro Tagliaferri

Per informazioni sull’arruolamento contattare: Dott.ssa Luigia Gervasi (Tel: 0961-3647921) Email: luigiagervasi@gmail.com

 


Studi clinici chiusi all’arruolamento

Titolo: DZB-CS-202 – “A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03)”

Principal Investigator: Prof. Pierfrancesco Tassone